ライフサイエンスコーパス: ophthalmopathy

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 te the underlying autoimmune pathogenesis of ophthalmopathy.

2 lower lid retraction in patients with Graves ophthalmopathy.

3 in patients with active, moderate-to-severe ophthalmopathy.

4 king increases the risk and relapse rate for ophthalmopathy.

5 a major controllable risk factor for thyroid ophthalmopathy.

6 is for the immunologic attack seen in Graves ophthalmopathy.

7 g to the clinical findings typical of Graves ophthalmopathy.

8 sociated with the appearance or worsening of ophthalmopathy.

9 sic questions about the treatment of thyroid ophthalmopathy.

10 intense inflammation associated with Graves' ophthalmopathy.

11 Thyroid-associated ophthalmopathy, a condition commonly associated with Gra

12 Thyroid-associated ophthalmopathy and dermopathy are connective tissue mani

13 The pathogenesis of thyroid ophthalmopathy and its relation to thyroid gland dysfunc

14 in the etiology and pathobiology of Graves' ophthalmopathy and/or other ocular myopathies.

15 of >/=3 indicating active thyroid-associated ophthalmopathy) and a reduction of 2 mm or more in propt

16 Graves' ophthalmopathy (GO) affects 50% to 60% of patients with

17 Appearances of and increases in Graves' ophthalmopathy (GO) have been reported after treatment o

18 Graves ophthalmopathy (GO) is an autoimmune disease that typica

19 (GD) is a common thyroid disease, and Graves ophthalmopathy(GO) is the most common extra-thyroidal ma

20 The surgical management of Graves ophthalmopathy includes treatment of globe malposition (

21 se undergoing the orbital changes of Graves' ophthalmopathy is often challenging, even as our underst

22 onnective tissues seen in thyroid-associated ophthalmopathy is unknown.

23 Stickler syndrome (hereditary arthro-ophthalmopathy) is the commonest inherited cause of reti

24 ations, for example, Duane syndrome, Graves' ophthalmopathy, may be particularly problematic.

25 The restrictive ophthalmopathy of TAO may be associated with more sustai

26 The Graves' Ophthalmopathy Quality of Life (GO-QOL) scale was comple

27 l Activity Score, and results on the Graves' ophthalmopathy-specific quality-of-life questionnaire.

28 Thyroid-associated ophthalmopathy (TAO) is a common and debilitating manife

29 Thyroid-associated ophthalmopathy (TAO), an autoimmune component of Graves'

30 ed in the pathogenesis of thyroid-associated ophthalmopathy (TAO), the orbital manifestation of GD, r

31 ue remodeling linked with thyroid-associated ophthalmopathy (TAO).

32 This process is known as thyroid-associated ophthalmopathy (TAO).

33 ity of the human orbit to thyroid-associated ophthalmopathy (TAO).

34 c markers for more severe thyroid-associated ophthalmopathy (TAO).

35 le in the pathogenesis of thyroid-associated ophthalmopathy (TAO).

36 In patients with active ophthalmopathy, teprotumumab was more effective than pla

37 vement of the extraocular muscles in Graves' ophthalmopathy, the absence of N-CAM expression on other

38 fat accumulation, such as occurs in Graves' ophthalmopathy, tissue fibrosis, abnormal wound healing,

39 suggests that it may play a role in thyroid ophthalmopathy treatment and prevention.

40 retrospective review of patients with Graves ophthalmopathy undergoing lower eyelid retraction surger

41 al, specific diagnostic criteria for thyroid ophthalmopathy were established and are included in this

42 Medical records for patients with dysthyroid ophthalmopathy who underwent bilateral lateral rectus re

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。